多西他赛所致手足综合征：五例病例系列报道 - Suppr

Suppr

超能文献

Hand-foot syndrome with docetaxel: a five-case series.

作者信息

Farhat Mirna H, El-Saghir Nagi S, Shamseddine Ali I

机构信息

Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

出版信息

Ann Saudi Med. 2008 Sep-Oct;28(5):374-7. doi: 10.5144/0256-4947.2008.374.

DOI:10.5144/0256-4947.2008.374

PMID:18779636

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6074482/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/475f/6074482/27989c43d392/asm-5-374f1.jpg

相似文献

Hand-foot syndrome with docetaxel: a five-case series.

Ann Saudi Med. 2008 Sep-Oct;28(5):374-7. doi: 10.5144/0256-4947.2008.374.

Hand and foot syndrome associated with docetaxel treatment.

Acta Oncol. 2012 Apr;51(4):554-6. doi: 10.3109/0284186X.2011.636755. Epub 2011 Nov 30.

Hand-foot syndrome after treatment with docetaxel.

Med J Aust. 2009 Jul 6;191(1):40. doi: 10.5694/j.1326-5377.2009.tb02675.x.

Docetaxel-induced skin toxicity.

Neth J Med. 2009 Jan;67(1):33-4.

High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.

Ann Oncol. 2003 Nov;14(11):1691-2. doi: 10.1093/annonc/mdg446.

Penile involvement with hand-foot syndrome.

Am J Clin Dermatol. 2004;5(3):209-10. doi: 10.2165/00128071-200405030-00010.

Interstitial granulomatous drug reaction to sorafenib.

Arch Dermatol. 2011 Sep;147(9):1118-9. doi: 10.1001/archdermatol.2011.241.

A case of docetaxel-induced erythrodysesthesia.

J Dermatol. 2004 May;31(5):403-6. doi: 10.1111/j.1346-8138.2004.tb00692.x.

[Dermatologic toxicity to sorafenib].

Actas Dermosifiliogr. 2009 Jul-Aug;100(6):518-20.

[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].

Ugeskr Laeger. 2003 Aug 11;165(33):3161-2.

引用本文的文献

Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients.

Support Care Cancer. 2022 Feb;30(2):1539-1546. doi: 10.1007/s00520-021-06573-3. Epub 2021 Sep 18.

Hand Foot Syndrome Secondary to Low Dose Docetaxel.

Int J Health Sci (Qassim). 2015 Jul;9(3):335-7.

Management of Paclitaxel-induced hand-foot syndrome.

Breast Care (Basel). 2013 Jun;8(3):215-7. doi: 10.1159/000352097.

Docetaxel-induced hand foot syndrome: "No dose is a safe dose".

J Pharmacol Pharmacother. 2012 Apr;3(2):200-1. doi: 10.4103/0976-500X.95534.

本文引用的文献

Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.

Clin Colorectal Cancer. 2006 Sep;6(3):219-23. doi: 10.3816/CCC.2006.n.039.

Management of hand-foot syndrome induced by capecitabine.

J Oncol Pharm Pract. 2006 Sep;12(3):131-41. doi: 10.1177/1078155206069242.

Three case reports of hand-foot syndrome with gefitinib.

Cancer Invest. 2006 Aug-Sep;24(5):514-6. doi: 10.1080/07357900600814847.

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.

Clin Breast Cancer. 2006 Jun;7(2):141-5. doi: 10.3816/CBC.2006.n.023.

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.

J Clin Oncol. 2006 May 1;24(13):e18-9. doi: 10.1200/JCO.2006.06.1143.

Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.

Breast. 2006 Jun;15(3):414-24. doi: 10.1016/j.breast.2005.07.007. Epub 2005 Sep 26.

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.

J Clin Oncol. 2005 Jul 1;23(19):4424-9. doi: 10.1200/JCO.2005.15.651.

Palmar-plantar erythrodysesthesia.

Clin J Oncol Nurs. 2005 Feb;9(1):103-6. doi: 10.1188/05.CJON.103-106.

Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4.

A case of docetaxel-induced erythrodysesthesia.

J Dermatol. 2004 May;31(5):403-6. doi: 10.1111/j.1346-8138.2004.tb00692.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Hand-foot syndrome with docetaxel: a five-case series.

Ann Saudi Med. 2008 Sep-Oct;28(5):374-7. doi: 10.5144/0256-4947.2008.374.

Hand and foot syndrome associated with docetaxel treatment.

Acta Oncol. 2012 Apr;51(4):554-6. doi: 10.3109/0284186X.2011.636755. Epub 2011 Nov 30.

Hand-foot syndrome after treatment with docetaxel.

Med J Aust. 2009 Jul 6;191(1):40. doi: 10.5694/j.1326-5377.2009.tb02675.x.

Docetaxel-induced skin toxicity.

Neth J Med. 2009 Jan;67(1):33-4.

High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.

Ann Oncol. 2003 Nov;14(11):1691-2. doi: 10.1093/annonc/mdg446.

Penile involvement with hand-foot syndrome.

Am J Clin Dermatol. 2004;5(3):209-10. doi: 10.2165/00128071-200405030-00010.

Interstitial granulomatous drug reaction to sorafenib.

Arch Dermatol. 2011 Sep;147(9):1118-9. doi: 10.1001/archdermatol.2011.241.

A case of docetaxel-induced erythrodysesthesia.

J Dermatol. 2004 May;31(5):403-6. doi: 10.1111/j.1346-8138.2004.tb00692.x.

[Dermatologic toxicity to sorafenib].

Actas Dermosifiliogr. 2009 Jul-Aug;100(6):518-20.

[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].

Ugeskr Laeger. 2003 Aug 11;165(33):3161-2.

引用本文的文献

Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients.

Support Care Cancer. 2022 Feb;30(2):1539-1546. doi: 10.1007/s00520-021-06573-3. Epub 2021 Sep 18.

Hand Foot Syndrome Secondary to Low Dose Docetaxel.

Int J Health Sci (Qassim). 2015 Jul;9(3):335-7.

Management of Paclitaxel-induced hand-foot syndrome.

Breast Care (Basel). 2013 Jun;8(3):215-7. doi: 10.1159/000352097.

Docetaxel-induced hand foot syndrome: "No dose is a safe dose".

J Pharmacol Pharmacother. 2012 Apr;3(2):200-1. doi: 10.4103/0976-500X.95534.

本文引用的文献

Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.

Clin Colorectal Cancer. 2006 Sep;6(3):219-23. doi: 10.3816/CCC.2006.n.039.

Management of hand-foot syndrome induced by capecitabine.

J Oncol Pharm Pract. 2006 Sep;12(3):131-41. doi: 10.1177/1078155206069242.

Three case reports of hand-foot syndrome with gefitinib.

Cancer Invest. 2006 Aug-Sep;24(5):514-6. doi: 10.1080/07357900600814847.

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.

Clin Breast Cancer. 2006 Jun;7(2):141-5. doi: 10.3816/CBC.2006.n.023.

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.

J Clin Oncol. 2006 May 1;24(13):e18-9. doi: 10.1200/JCO.2006.06.1143.

Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.

Breast. 2006 Jun;15(3):414-24. doi: 10.1016/j.breast.2005.07.007. Epub 2005 Sep 26.

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.

J Clin Oncol. 2005 Jul 1;23(19):4424-9. doi: 10.1200/JCO.2005.15.651.

Palmar-plantar erythrodysesthesia.

Clin J Oncol Nurs. 2005 Feb;9(1):103-6. doi: 10.1188/05.CJON.103-106.

Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4.

A case of docetaxel-induced erythrodysesthesia.

J Dermatol. 2004 May;31(5):403-6. doi: 10.1111/j.1346-8138.2004.tb00692.x.